A Phase I, Open-label, Multicenter Study to Evaluate the Safety and Tolerability of BP2202 in Patients With Relapsed/Refractory Multiple Myeloma

Trial statusNot yet recruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18+

SponsorBrightPath Biotherapeutics Co., Ltd.

About this trial

The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed/Refractory Multiple Myeloma.

Diagnosis of Multiple Myeloma with relapsed or refractory disease.

Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1

Adequate organ function.

Have measurable disease

Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of Multiple Myeloma.

Known second malignancy that is progressing or requires active treatment or may interfere with study endpoints.

18 Participants

are divided into 1 treatment group

This trial has no locations

BrightPath Biotherapeutics Co., Ltd.

Lead sponsor